

1 **Epidemiological Analysis of Confirmed Mpox Cases in Burundi, July to September 2024**

2

3 Alexis Nizigiyimana^{1#}, Francois Ndikumwenayo², Martin Manirakiza^{2,3}, Monique van Lettow^{4,5},
4 Adrienne K. Chan^{5,6,7}, Laurens Liesenborghs⁸, Placide Mbala-Kingebeni^{9,10}, Anne W. Rimoin¹¹,
5 Isaac I. Bogoch¹², Jason Kindachuk^{13,14#}

6

7 ¹Department of Management, Evaluation and Health Policy, School of Public Health, Université
8 de Montréal, Montreal, QC, Canada

9 ²University of Burundi, Bujumbura, Bujumbura, Burundi

10 ³Burundi NCD Alliance, Bujumbura, Burundi

11 ⁴Madiro, Toronto, Canada.

12 ⁵Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

13 ⁶Infection Prevention and Control, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

14 ⁷Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, ON,
15 Canada

16 ⁸Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

17 ⁹Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the
18 Congo

19 ¹⁰Service de Microbiologie, Département de Biologie Médicale, Cliniques Universitaires de
20 Kinshasa, Université de Kinshasa

21 ¹¹Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA,
22 USA

23 ¹²Department of Medicine, University of Toronto, Toronto, ON, Canada

24 ¹³Department of Medical Microbiology and Infectious Diseases, University of Manitoba,
25 Winnipeg, MB, Canada

26 ¹⁴Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

27

28

29

30

31 #Corresponding Authors: Alexis Nizigiyimana (alexis.nizigiyimana@madiro.org); Jason
32 Kindrachuk (Jason.Kindrachuk@umanitoba.ca)

33 **ABSTRACT**

34 This study analyzes mpox cases in Burundi from July to September 2024, following the
35 introduction of Clade Ib. During this time, 25.4% of 607 samples tested positive via PCR.
36 Children under 15 comprised 55.2% of cases, with a higher proportion of female children testing
37 positive. Geographic analysis demonstrates case concentration in Bujumbura Mairie (59.1%).
38 These findings highlight the importance of age- and sex-specific interventions for outbreak
39 containment and the need for targeted public health strategies in Burundi.

40

41 **INTRODUCTION**

42 Mpox is a zoonotic viral infectious disease first identified in the Democratic Republic of the
43 Congo (DRC) in 1970 (1-3). Monkeypox virus (MPXV) historically circulated in the tropical
44 forest regions of Central and West Africa, where it is considered endemic (4, 5). The virus is
45 subclassified into two clades: clade I, formerly known as the Congo Basin (Central Africa) clade,
46 and clade II, formerly known as the West African clade. Clade II is further subdivided into two
47 subclades: IIa and IIb, with the latter responsible for the global epidemic in 2022 (6, 7).

48 Historically, zoonosis has been the primary driver of MPXV infections in humans with secondary
49 infections through human-to-human contact. However, Clade IIb MPXV infections during the
50 2022 global epidemic were linked primarily to sustained human-to-human transmission (8)
51 including within the men who have sex with men (MSM) community (9). The emergence of
52 Clade Ib MPXV in South Kivu, DRC, has demonstrated similar transmission characteristics that
53 have included linkage to sexual networks and sustained human-to-human transmission (10).

54 However, unlike Clade IIb infections, Clade Ib mpox cases have not been overrepresented among
55 males in South Kivu. Further, recent expansion of Clade Ib into North Kivu, DRC, has included
56 probable transmission through non-sexual or intimate contacts that have included children. While
57 there may be reporting biases complicating a more wholesome understanding of mpox
58 epidemiology, containment and mitigation strategies in this ongoing public health emergency
59 must consider these clade-specific demographic considerations for mpox acquisition.

60 The ongoing historic national outbreak in DRC has resulted in international expansion of Clade
61 Ib MPXV to multiple countries within the region including Kenya, Rwanda, Uganda, and

62 Burundi. This has resulted in the first declaration of a public health emergency of continental
63 security by the Africa CDC and the second declaration of a public health emergency of
64 international concern for mpox by the World Health Organization. Concerningly, mpox cases in
65 Burundi have demonstrated an increasing trajectory following Clade Ib introduction that has
66 included broad geographic expansion to many provinces. Here, we provide an analysis of
67 demographic and epidemiological considerations for mpox in Burundi using mpox case data
68 from July to September 2024.

69

70 **RESULTS**

71 We analyzed national mpox testing and demographic data acquired in Burundi from 03 July
72 2024 to 09 September 2024. During this period, 14 samples were tested in July, with 349 tested
73 in the month of August, and 244 for September up to 09 September 2024 for a total of 607
74 samples tested by PCR for MPXV (Table 1). Of these, men comprised 305 samples (50.2%) and
75 women comprised 302 samples (49.8%). For all samples, 154 samples (25.4%) tested positive,
76 448 samples (73.8%) tested negative, and 5 samples (0.8%) were indeterminate. Of the positive
77 samples, most positive tests were from men (80/154; 51.9%) with women comprising 48.1% of
78 positive cases (74/154). Negative samples were nearly evenly split between men (223/448;
79 49.8%) and women (225/448; 50.2%).

80 In analyzing age demographics, the median age of all individuals tested was 7 years (IQR: 2-18
81 years) (Table 2). For mpox-positive cases, the median age was 9.5 years (IQR: 3-25 years). For
82 males, the median age of positive cases was 17.5 years (IQR: 4.8-28.5 years). In contrast, the
83 median age of females who tested positive was 6 years (IQR: 2-20 years). The median age of
84 males and females that tested negative were similar at 7 years (IQR: 2-17.5 years) and 6 years
85 (IQR: 2-14 years), respectively.

86 In analyzing overall age demographics with mpox positivity, children <15 years comprised the
87 majority of all positive cases (85/154; 55.2%) (Table 3). This was followed by those aged 15-30
88 years (45/154; 29.2%) and lastly individuals 30+ years (24/154; 15.6%). When factoring in sex
89 and age with mpox positivity, there was a greater proportion of females (47/154; 30.5%) than
90 males (38/154; 24.7%) for children <15 years. Proportions were comparable between females

91 and males for those 15-30 years at 13.6% (21/154) and 15.6% (24/154), respectively. For those
92 aged 30+ years, there was a greater proportion of males (18/154; 11.7%) than females (6/154;
93 3.9%).

94 We also assessed the geographic distribution of positive cases in Burundi (Table 4). Mpox
95 positive cases were identified from 14 provinces in Burundi with the majority of positive cases
96 identified in Bujumbura Mairie (91/154; 59.1%) followed by Bubanza, Bujumbura, and Kayanza
97 with 10 cases reported from each (6.5% of positive cases). Associations between geographic
98 regions and age distribution of cases were limited due to the high proportion of overall mpox
99 cases reported from Bujumbura Mairie and much lower proportions in any of the other provinces
100 reporting. We did analyze age demographics in Bujumbura Mairie as compared to the complete
101 national data set. When focusing on Bujumbura Mairie, where 59.1% (91/154) of all mpox cases
102 were reported, children <15 years comprised 45% of cases (44/91), followed by those aged 15-30
103 years at 35.2% (32/91) and lastly those 30+ years with 16.5% of cases (15/91). When combining
104 positive case data from all other provinces (63 cases total), children <15 years comprised the
105 highest proportion of all cases at 65.1% (41/63), followed by those aged 15-30 years at 20.6%
106 (13/63) and those 30+ years at 14.3% (9/63).

107 Hospitalization data for confirmed mpox cases was available up to 25 September 2024 for a total
108 of 254 cases with 247 requiring care for more than one day (Table 5). Of these, 45 currently
109 remain in hospital, including 20 females and 25 males. The median age of those hospitalized was
110 19 (IQR: 8-28) with females being younger than males at 16 years (IQR: 7-25) versus 22 (IQR:
111 8-32), respectively. The overall duration of hospital admission was 8 days (IQR: 6-12) with
112 females and males having very similar hospitalization durations at 8 days (IQR: 5-9.8) and 9
113 days (IQR: 6-12), respectively. In regard to comorbidities among those hospitalized, none were
114 noted for the majority of the patients including 107 females and 124 males (231 cases total).
115 Among the hospitalized female cases, HIV positivity was noted among 6 patients, followed by
116 hypertension (3 cases), asthma (2 cases), and diabetes (1 case). For the hospitalized male cases,
117 the most prominent comorbidities were hypertension (4 cases), asthma (3 cases), diabetes (3
118 cases), and HIV (1 case).

119

120 **DISCUSSION**

121 From January 2023 to present, broad geographic expansion of Clade I MPXV in the DRC has
122 resulted in the largest mpox outbreak in recorded history among all endemic countries.
123 Concerningly, this national outbreak has included the expansion of MPXV to all provinces in
124 DRC as well as the emergence of a new virus subclade, Clade Ib, associated with sustained
125 human-to-human transmission (10). While first reported in South Kivu province, DRC, Clade Ib
126 has undergone rapid regional expansion that has included introduction to North Kivu, DRC (11),
127 as well as dissemination to neighbouring countries in East Africa, including Uganda, Rwanda,
128 Kenya, and most notably Burundi.

129 Here, we provide the first assessments of demographic, epidemiological, and hospitalization data
130 from suspected and confirmed mpox cases in Burundi from 03 July 2024 to 09 September 2024.
131 During this period, 607 suspected mpox cases underwent PCR testing with an overall mpox
132 positivity rate of 25.4%. This report provides important insights into Clade Ib mpox cases. Our
133 analysis of sex and mpox positivity did not demonstrate a strong indication of sex-specific
134 determinates with both a 0.5-1% difference between males and females when considering PCR
135 positive or negative results only. However, sex-specific differences were present when
136 considering age, mpox positivity, and hospitalization. While the median ages of males and
137 females were very similar among mpox negative cases (7 years and 6 years, respectively) there
138 was a large median age difference between males and females for mpox positive cases (17.5
139 years and 6 years, respectively), highlighting potential disparate sex-based epidemiologic risk
140 factors for infection. Further segregation of the data into age range groups showed that females
141 had a higher PCR positivity as compared to males for children <15 years whereas these trends
142 were reversed when considering those aged 30+ years. Males also had a slightly higher mpox
143 positivity percentage when considering those aged 15-30 years; however, this difference was
144 lowest amongst the age groupings. When considering hospitalization, females with mpox tended
145 to be younger than males (16 years compared to 22 years); however, the durations of
146 hospitalization were very similar at 8 days and 9 days, respectively. No fatalities were noted
147 among these patients though there were individuals still hospitalized at the time of this reporting.
148 Thus, this early data suggests that female mpox patients requiring hospitalization tended to be
149 younger than their male counterparts, there were no obvious indications of differences in
150 outcome or severity. These data provide important considerations for mpox response and
151 containment efforts in Burundi. Notably, this early epidemiological data suggests that female

152 children may be at higher risk for infection acquisition than their male counterparts whereas
153 males >30 years appear to be at higher risk for infection than females. Whether these data are
154 reflective of certain activities or behaviours associated with greater risk of MPXV infection
155 across sex and age groups needs to be addressed. An additional important consideration from this
156 data is that while mpox cases in Burundi were overrepresented among children <15 years, the
157 median age of hospitalization for both males and females was >15 years, unlike Clade Ia where
158 the highest morbidity and mortality have been among children historically. Considerations
159 should include assessment of potential reporting biases by sex and age as well as activities
160 among these groups that may be associated with higher infection risks (e.g. household
161 caregiving, contact with contaminated materials). It is also prudent to consider recent data for
162 Clade Ib infections from North Kivu which included probable non-sexual (intimate) contact-
163 based transmission events within and outside of households, including children (11). Thus,
164 community engagement and messaging activities in Burundi should consider these early
165 associations between mpox positivity status, sex, and age.

166 Geographic associations with mpox cases were perhaps unsurprising as the majority of cases
167 were identified in Bujumbura Mairie Province (59.1%), which includes the city of Bujumbura
168 alone. The remaining cases were split among 13 additional provinces in Burundi with cases
169 ranging from 1 to 10 reported per province. Mpox testing data did not include specific
170 geographic residences for individuals. Thus, whether the overrepresentation of cases within
171 Bujumbura Mairie is indicative of local mpox transmission alone, includes non-residents
172 reporting in the province due to healthcare and testing availability, or a combination thereof
173 should be considered.

174 This report provides an early assessment of the demographic and epidemiological characteristics
175 of Clade Ib mpox cases in Burundi and provide important insights for ongoing outbreak
176 containment and mitigation strategies, including community engagement and messaging
177 activities.

178

179 **ETHICS STATEMENT**

180 Data was provided by country-wide mpox surveillance program. Permission to use this data was
181 granted by the Institutional Ethics Committee at the Faculty of Medicine, University of Burundi
182 (CIEB-FMCHUK no. 02/09/2024).

183

184 **DATA AVAILABILITY**

185 All data produced in the present study are available upon reasonable request to the authors.

186

187 **FUNDING**

188 Funding for the work presented was provided by the International Mpox Research Consortium
189 (IMReC) through funding from the Canadian Institutes of Health Research and International
190 Development Research Centre (grant no. MRR-184813).

191

192 **CONFLICT OF INTEREST**

193 IIB consults to the Weapons Threat Reduction Program at Global Affairs Canada.

194

195

196 **REFERENCES**

- 197 1. Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human
198 monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):165-82.
- 199 2. Foster SO, Brink EW, Hutchins DL, Pifer JM, Lourie B, Moser CR, et al. Human
200 monkeypox. Bull World Health Organ. 1972;46(5):569-76.
- 201 3. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in
202 Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ.
203 1972;46(5):593-7.

- 204 4. Van Dijck C, Hoff NA, Mbala-Kingebeni P, Low N, Cevik M, Rimoin AW, et al.
205 Emergence of mpox in the post-smallpox era-a narrative review on mpox epidemiology. Clin
206 Microbiol Infect. 2023;29(12):1487-92.
- 207 5. Okwor T, Mbala PK, Evans DH, Kindrachuk J. A contemporary review of clade-specific
208 virological differences in monkeypox viruses. Clin Microbiol Infect. 2023;29(12):1502-7.
- 209 6. Ulaeto D, Agafonov A, Burchfield J, Carter L, Happi C, Jakob R, et al. New
210 nomenclature for mpox (monkeypox) and monkeypox virus clades. Lancet Infect Dis.
211 2023;23(3):273-5.
- 212 7. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al.
213 Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N Engl J Med.
214 2022;387(8):679-91.
- 215 8. WHO. 2022-23 Mpox (Monkeypox) Outbreak: Global Trends. 2023.
- 216 9. Tarin-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suner C, Anton A, et al. Clinical
217 presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a
218 prospective observational cohort study. Lancet. 2022;400(10353):661-9.
- 219 10. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole A, Wawina-Bokalanga T,
220 Mukadi-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern
221 Democratic Republic of the Congo. Nat Med. 2024.
- 222 11. Mukadi-Bamuleka D K-LE, Mulopo-Mukanya N, Amuri-Aziza A, O'Toole A et al. First
223 imported Cases of MPXV Clade Ib in Goma, Democratic Republic of the Congo: Implications
224 for Global Surveillance and Transmission Dynamics. medRxiv. 2024.

225

226 TABLES

227 **Table 1: Mpox test results in Burundi by sex.**

	Negative	Indeterminate	Positive
Male	223 (49.8%)	2 (0.33%)	80 (13.2%)
Female	225 (50.2%)	3 (0.49%)	74 (12.2%)
Total	448 (73.8%)	5 (0.82%)	154 (25.4%)

228

229 **Table 2: Age demographics for individuals tested for mpox in Burundi.**

	Median Age (years) Mpox +ve	Median Age (years) Mpox -ve
Male	17.5 (IQR: 4.8-28.5)	7 (IQR: 2-17.5)
Female	6 (IQR: 2-20)	6 (IQR: 2-14)
Total	9.5 (IQR: 3-25)	6 (IQR: 2-15)

230

231 **Table 3: Age demographics by sex for all individuals with confirmed mpox.**

	All	Male	Female
<15 years	85 (55.2%)	38 (24.7%)	47 (30.5%)
15-30 years	45 (29.2%)	24 (15.6%)	21 (13.6%)
30+ years	24 (15.6%)	18 (11.7%)	6 (3.90%)

232

233 **Table 4: Confirmed mpox cases by province.**

Province	Cases Reported
Bubanza	10 (6.49%)
Bujumbura	10 (6.49%)
Bujumbura Mairie	91 (59.1%)
Bururi	2 (1.30%)
Cibitoke	1 (0.65%)
Gitega	5 (3.25%)
Karusi	3 (1.95%)
Kayanza	10 (6.49%)
Makamba	1 (0.65%)
Muramvya	5 (3.25%)
Muyinga	7 (4.55%)
Mwaro	1 (0.65%)

Rumonge	3 (1.95%)
Ruyigi	5 (3.25%)
Total	154

234

235 **Table 5: Hospitalization data in Burundi up to 25 September 2024.**

	Total Hospitalizations	Median Age (years)	Duration of Care (days)
Male	132	22 (IQR: 8-32)	9 (IQR: 6-12)
Female	115	16 (IQR: 7-25)	8 (IQR: 5-9.8)
Total	247	19 (IQR: 8-28)	8 (IQR: 6-12)

236

237